story of the week
Glycemic Durability of Early Combination Therapy With Vildagliptin and Metformin vs Sequential Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Glycaemic Durability of an Early Combination Therapy With Vildagliptin and Metformin Versus Sequential Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes (VERIFY): A 5-Year, Multicentre, Randomised, Double-Blind Trial
Lancet 2019 Sep 17;[EPub Ahead of Print], DR Matthews, PM Paldánius, P Proot, Y Chiang, M Stumvoll, S Del PratoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.